People Are Asking ChatGPT for Advice on Injecting Their Own Facial Filler, a Cosmetic Procedure That Should Only Be Carried Out by Licensed Medical Professionals
Now add to that list: asking ChatGPT for advice on how to inject facial filler — a trendy cosmetic procedure intended to puff up features like lips and cheeks — at home, without the assistance of a medical professional.
"I'll be injecting myself tonight," one Redditor wrote in a recent post. "I have all things needed on hand and I'm trying to research the best way of keeping things as sterile/clean as possible. I asked ChatGPT and it said I should absolutely not use normal gloves, I googled and can't find any specific info on it."
Needless to say, this is a resoundingly terrible idea. Please don't do this procedure at home, and instead go to a qualified medical facility so you don't hurt yourself. (While pros can screw up this process too, at least they can be held liable.)
Unfortunately, nobody chastised the Redditor for asking ChatGPT for advice. In fact, a quick perusal of the same subreddit, where thrifty beauty aficionados swap tips on administering cosmetic procedures on their own, finds a huge number of similarly alarming situations.
"I used ChatGPT to help me map my tox and PN placements, how to dilute my tox facial and depth of injections, etc," one commenter enthused. "If you send it annotated photos it can view your mapping and correct it."
Another user turned to AI after problems with a DIY cosmetic procedure.
"Asked [ChatGPT], and it said that since a small amount likely migrated to cheek area through tear trough [sic]," they wrote. "But since it migrated, likely was dissolved into bloodstream. Fibrosis possible but may resolve. If fat was dissolved it should be very negligible."
AI models may be set to revolutionize medicine in certain ways, such as at the Icahn School of Medicine at Mount Sinai, which is incorporating AI into training doctors. Researchers are excited about AI being used to diagnose diseases such as prostate cancer and heart disease earlier than before.
But the jury is still out on how effective AI chatbots will be in dispensing useful medical advice. For example, a recent npj Digital Medicine paper in March revealed that while large language models such as ChatGPT are more accurate than search engines, they are still going to spew out more than 30 percent of incorrect advice under certain circumstances.
In addition, the quality of output is reliant on the quality of the prompt.
"We found that some input prompts, which guide the models towards reputed sources, are much more effective than basic prompts (or prompts that give no context at all)," the researchers wrote. "However, lay users would hardly resort to sophisticated prompts or complex interactions with the LLMs."
In a nutshell, sure you can ask ChatGPT questions — but please confer with a real doctor before undertaking any treatment, especially if you're doing it at home.
More on ChatGPT: Man Annoyed When ChatGPT Tells Users He Murdered His Children in Cold Blood

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
New York Life Named a Strategic Workday Wellness Partner to Streamline Employer Benefits Administration
New York Life Group Benefit Solutions reinforces its commitment to simple, connected benefits experiences as a strategic Workday Wellness Partner NEW YORK, August 20, 2025--(BUSINESS WIRE)--New York Life Group Benefit Solutions (NYL GBS) today announced it has been named a strategic Workday Wellness partner. Through this partnership, NYL GBS will integrate with Workday Wellness, empowering employers with AI-driven insights to help improve benefit offerings and streamline their benefits administration. Workday Wellness is an AI-powered solution that enhances employee benefits experiences by sharing a real-time view into the benefits and wellness offerings employees use and value most. This partnership aims to deliver greater administrative efficiency for employers and provide actionable insights that maximize engagement with both employers and employees. Employers gain powerful tools to measure effectiveness of their benefit offerings and dynamically adapt those benefits to better meet their employees' needs. "Benefit solutions should evolve to meet employers' changing needs, centered on a seamless and integrated end-to-end benefits experience," said Kristina Welke, vice president, Strategy, Solutions, Marketing at New York Life Group Benefit Solutions. "At NYL GBS, we prioritize understanding what employers and employees truly need, ensuring that our solutions remain both relevant and impactful. Our partnership with Workday will enable us to drive efficiency and reduce work for employers through advanced digital integration and real-time data connections." NYL GBS delivers benefits experiences powered by people and enhanced by technology. As part of this commitment, NYL GBS's Workday Consulting team partners with clients to provide consultative support for onboarding API integrations. This human-centered approach reflects NYL GBS's broader purpose: to simplify benefits administration and enable HR teams to focus on what matters most—their people. Workday Wellness was recently recognized as a Top HR Product of 2025 by HR Executive for helping organizations better understand the impact of their benefits programs and adapt their offerings to meet the needs of their workforce. For more information on New York Life's employer benefits solutions, visit ABOUT NEW YORK LIFE New York Life Insurance Company ( a Fortune 100 company founded in 1845, is the largest mutual life insurance company in the United States¹ and one of the largest life insurers in the world. Headquartered in New York City, New York Life's family of companies offers life insurance, disability income insurance, retirement income, investments, and long-term care insurance. The company holds the highest financial strength ratings currently awarded to any U.S. life insurer by all four major credit rating agencies². WORKDAY® and the Workday logos are trademarks of Workday, Inc., registered in the United States and elsewhere. All other marks are the property of their respective owners. Workday Wellness and the issuers of New York Life Group Benefit Solutions are independent entities and each entity is responsible for the products and services that it provides. 1 Based on revenue as reported by "Fortune 500 ranked within Industries, Insurance: Life, Health (Mutual)," Fortune magazine, 6/2/2025. For methodology, see 2 Individual independent rating agency commentary as of 5/19/2025: A.M. Best (A++), Fitch (AAA), Moody's (Aa1), Standard & Poor's (AA+). View source version on Contacts Media Contact: Domenic CuzzolinaNew York Life Insurance Company(212) 576-5950Domenic_Cuzzolina@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Wearable Devices Collaborates with Leading Japanese E-Commerce Platform to Expand Mudra Wearable Devices in Tech-Savvy Market
Mudra wearable devices use neural sensors to enable touchless control of digital devices across Apple, Android and Windows platforms. Yokneam Illit, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (the 'Company' or 'Wearable Devices'), a technology growth company specializing in artificial intelligence ('AI')-powered touchless sensing wearables, recently announced a collaboration with Media Exceed Co., Ltd. ('Media Exceed'), a leading e-commerce company in Japan. Under this agreement, Media Exceed will serve as a non-exclusive reseller of the award-winning Mudra Band and Mudra Link, bringing Wearable Devices' innovative neural technology to Japan, one of the world's most tech-savvy consumer bases. This collaboration aims to enhance the availability of Wearable Devices' neural interface products in Japan, leveraging Media Exceed's robust e-commerce platform and market expertise. The collaboration supports both drop shipping and wholesale models, ensuring streamlined order fulfillment and localized customer support for Japanese buyers. See the Mudra Band and Mudra Link in action at 'This collaboration is a major step in our mission to revolutionize how people interact with technology,' said Asher Dahan, Chief Executive Officer of Wearable Devices. 'Japan's appetite for innovation makes it the perfect market to showcase our Mudra products, and we're thrilled to collaborate with Media Exceed to accelerate our global growth.' Shinya Kasuga, Chief Executive Officer of Media Exceed, said: 'We are eager to start working with Wearable Devices and bring the innovative Mudra products to the Japanese market. Their neural interface technology aligns perfectly with our vision to introduce cutting-edge solutions that enhance the way people interact with digital devices.' The Mudra Band, designed for Apple Watch users, and the Mudra Link, compatible with Android and Windows devices, utilize proprietary Surface Nerve Conductance sensors to detect neural signals from subtle finger movements. These signals are translated into intuitive commands, enabling touchless control of digital devices. The Mudra Link was recently showcased at CES® 2025, where it received an Innovation Award in the XR Technologies and Accessories category. Media Exceed will offer these products through its online platforms, providing Japanese consumers with direct access to Wearable Devices' innovative technology. The collaboration is expected to enhance user experience and satisfaction by combining advanced wearable technology with Media Exceed's customer-centric approach. About Wearable Devices Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company's consumer products - the Mudra Band and Mudra Link - are defining the neural input category both for wrist-worn devices and for brain-computer interfaces. These products enable touch-free, intuitive control of digital devices using gestures across multiple operating systems. Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and extended reality (XR). In the business sector, the Company provides enterprise partners with advanced input solutions for immersive and interactive environments, from augmented reality/virtual reality/XR to smart environments. By setting the standard for neural input in the XR ecosystem, Wearable Devices is shaping the future of seamless, natural user experiences across some of the world's fastest-growing tech markets. Wearable Devices' ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols 'WLDS' and 'WLDSW,' respectively. Forward-Looking Statements Disclaimer This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the 'safe harbor' created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'should,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'estimate,' 'anticipate' or other comparable terms. For example, we are using forward-looking statements when we discuss the aim of our collaboration with Media Exceed, benefits and advantages of our products and technology, that this collaboration is a major step in our mission to revolutionize how people interact with technology, that collaboration with Media Exceed will accelerate our global growth and that the collaboration is expected to enhance user experience and satisfaction. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2024, filed on March 20, 2025 and our other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact Michal Efraty IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry
BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously required massive platform investments by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service that could help scientists design better drugs with fewer resources. The new collaboration connects three core capabilities: (1) Ginkgo Datapoints' rapid ADME profiling, (2) Inductive Bio's model–driven chemistry design platform, and (3) Tangible Scientific's API-enabled compound management platform. Together, these capabilities aim to move from in-silico compound designs to validated experimental results in one digitally-enabled workstream, with fewer synthesis cycles, faster turnarounds, and lower overall drug discovery costs. Drug discovery has evolved far beyond the days when scientists would design, synthesize, and test compounds within a single facility. Today, the process is often a global logistics challenge — moving compounds across vendors and continents, introducing delays, and creating coordination bottlenecks. That fragmentation makes it harder to take advantage of AI-driven design and lab-in-the-loop workflows, where results are returned quickly integrated into models that inform the next design cycle. "The image of scientists sketching molecules on a whiteboard and then walking down the hall to synthesize and test them is long outdated," said John Androsavich, General Manager at Ginkgo Datapoints. "By tightly coupling model-driven design with streamlined logistics to deliver AI/ML-ready assay data in real-time, we're making it easier for scientists to iterate quickly, take advantage of cutting edge digital tools, and focus on what they do best — discovering treatments for patients." Lab-in-the-Loop EfficiencyBuilding on its announcement earlier this year of cost-competitive, fast-turnaround ADME services, Ginkgo is taking the next step in delivering innovative solutions in small molecule drug discovery through these partnerships. Ginkgo Datapoints' ADME profiling service delivers high-quality readouts — including microsomal stability, kinetic solubility, P450 inhibition, and permeability — with optional in vitro toxicity readouts on both lead candidates and library-scale compound sets. Ginkgo's services benefit from accelerated US-based logistics local to Boston's biopharma hub, in-house data infrastructure, and lab automation capabilities. Tangible Scientific, also strategically located near Boston, orchestrates the secure storage, handling, and rapid movement of customer compounds, with delivery to local service providers including Ginkgo. The company's tech-enabled platform unifies compounds, data, and decision-making into a single, automated pipeline. Using Tangible's platform, researchers can submit orders for Ginkgo's ADME services directly from their digital environments, receive real-time status notifications, access structured, metadata-rich assay results in days, not weeks, and instantly integrate those results into downstream design workflows. Inductive Bio's Compass platform allows chemists to explore and rank design ideas using fine-tuned ADMET prediction models trained on a broad consortium dataset. Designs can then be sent to Tangible and Ginkgo for experimental validation which are then fed back into the models, creating a lab-in-the-loop cycle that combines predictive accuracy with real-world results. Practical Step Toward Faster DevelopmentBy aligning design, experiment, and data delivery into a single connected process, the partnership aims to reduce the time and uncertainty in early-stage drug development. It also supports the FDA's push for faster, more efficient development timelines, onshored manufacturing and services, greater use of AI tools, and adoption of non-animal approaches in preclinical testing. AvailabilityThe services are available now and are tailored for pharmaceutical and biotech teams looking to improve ADMET optimization and reduce iteration times on programs and across portfolios. About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. About Tangible ScientificTangible Scientific's facility in Natick, MA, strategically located just outside Boston, is optimized for storing and managing customer assets with courier service to local providers, including Ginkgo. Through Tangible's platform, researchers can directly submit orders for Ginkgo's ADME services from their digital environments, receive real-time status notifications, and access structured, metadata-rich assay results in days, rather than weeks. This customer-first model eliminates the friction of traditional, fragmented operations, reducing errors, increasing speed, and freeing scientists to focus on discovery instead of internal and external coordination. About Inductive BioInductive Bio has developed a collaborative AI platform that dramatically accelerates compound optimization, a critical and time-consuming step in developing new therapeutics. By building a pre-competitive data consortium and state-of-the-art ML models designed to map the drivers of small molecule Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET), Inductive's platform allows scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties. Forward-Looking Statements of Ginkgo BioworksThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. GINKGO BIOWORKS INVESTOR CONTACT:investors@ GINKGO BIOWORKS MEDIA CONTACT:press@ View original content to download multimedia: SOURCE Ginkgo Bioworks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data